Eurobio Scientific Société anonyme (ENXTPA:ALERS) signed a definitive agreement to acquire EndoPredict business of Myriad Genetics, Inc (NasdaqGS:MYGN) for $10 million on May 6, 2024. The deal is subject to customary closing conditions, and Myriad expects the transaction to close in the second or third quarter of 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.5 EUR | -0.82% | -3.33% | -11.91% |
May. 08 | Eurobio Scientific: agreement with Myriad Genetics | CF |
May. 08 | Eurobio Scientific to Buy Gene Expression Test for Breast Cancer | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
22.7 USD | -2.66% | -5.38% | 2.11B | ||
14.5 EUR | -0.82% | -3.33% | 160M | ||
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-11.91% | 160M | |
+48.67% | 58.71B | |
-2.76% | 41.31B | |
+36.42% | 39.2B | |
-11.22% | 27.4B | |
+9.25% | 26.55B | |
-23.10% | 18.98B | |
+1.88% | 12.51B | |
+26.43% | 12.08B | |
+21.74% | 11.94B |
- Stock Market
- Equities
- ALERS Stock
- News Eurobio Scientific
- Eurobio Scientific Société anonyme signed a definitive agreement to acquire EndoPredict business of Myriad Genetics, Inc for $10 million.